Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Julie Mchugh sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $16.16, for a total value of $24,240.00. Following the sale, the director now directly owns 80,908 shares of the company’s stock, valued at $1,307,473.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Ironwood Pharmaceuticals, Inc. (IRWD) traded down 2.03% during trading on Friday, reaching $15.48. The company’s stock had a trading volume of 1,485,497 shares. The company’s market capitalization is $2.32 billion. Ironwood Pharmaceuticals, Inc. has a one year low of $12.48 and a one year high of $19.94. The firm’s 50-day moving average price is $15.80 and its 200-day moving average price is $17.09.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The firm had revenue of $65.10 million during the quarter, compared to analysts’ expectations of $70 million. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. Ironwood Pharmaceuticals’s revenue was up 19.7% on a year-over-year basis. On average, equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post ($1.10) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/09/julie-mchugh-sells-1500-shares-of-ironwood-pharmaceuticals-inc-irwd-stock.html.

A number of large investors have recently bought and sold shares of IRWD. Strs Ohio grew its position in Ironwood Pharmaceuticals by 132.1% in the 1st quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 3,700 shares during the period. Teacher Retirement System of Texas bought a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth approximately $192,000. Jane Street Group LLC bought a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $194,000. Karp Capital Management Corp bought a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $201,000. Finally, Raymond James Financial Services Advisors Inc. grew its position in Ironwood Pharmaceuticals by 8.0% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 898 shares during the period. 97.95% of the stock is owned by institutional investors and hedge funds.

A number of analysts have commented on IRWD shares. Mizuho reissued a “buy” rating and set a $22.00 price objective on shares of Ironwood Pharmaceuticals in a report on Sunday, July 23rd. BidaskClub raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Wells Fargo & Company set a $19.00 target price on Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, July 22nd. Cowen and Company set a $20.00 target price on Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Zacks Investment Research raised Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $18.13.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.